Enanta Pharmaceuticals | ENTA - Fremdkapital





Fremdkapital Veränderung Datum
AbbVie USD 58.94B 4.03B 2025-12
Amgen USD 51.89B 1.88B 2026-03
Arrowhead Research USD 1.23B 687.3M 2026-03
AstraZeneca USD 25.96B 177M 2026-03
BioCryst Pharmaceuticals USD 395.2M 33.48M 2026-03
Biogen USD 6.29B 1.7M 2026-03
Bristol-Myers Squibb USD 42.15B 698M 2026-03
Enanta Pharmaceuticals USD 0 0 2024-12
Gilead Sciences USD 20.86B 1.27B 2026-03
GlaxoSmithKline GBP 14.01B 696M 2026-03
Halozyme Therapeutics USD 1.94B 206.73M 2026-03
Heron Therapeutics USD 140.64M 975K 2025-12
Immunic USD 0 0 2024-06
Incyte USD 29.41M 785K 2026-03
Insmed USD 542.22M 1.25M 2026-03
Ionis Pharmaceuticals USD 1.91B 9M 2026-03
J&J USD 37.53B 1.91B 2026-03
Karyopharm Therapeutics USD 278.22M 278.22M 2025-12
Ligand Pharmaceuticals USD 446.19M 702K 2025-12
Merck USD 46.67B 77M 2026-03
Neurocrine Biosciences USD 169.5M 500K 2023-03
Novartis USD 37.45B 7.86B 2026-03
Novavax USD 246.3M 200K 2025-12
Pfizer USD 60.57B 1.08B 2026-03
PTC Therapeutics USD 286.94M 1.74B 2026-03
Roche Holding CHF 27.43B 966M 2025-12
Sarepta Therapeutics USD 838.16M 9.19M 2026-03
Vertex Pharmaceuticals USD 106.7M 4.7M 2025-12